Healthdirect Free Australian health advice you can count on.

Medical problem? Call 1800 022 222. If you need urgent medical help, call triple zero immediately

healthdirect Australia is a free service where you can talk to a nurse or doctor who can help you know what to do.

beginning of content

Brand name: Femoston 2/10

Femoston 2/10 is a medicine containing the active ingredient(s) estradiol, estradiol + dydrogesterone. On this page you will find out more about Femoston 2/10, including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)

You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.

Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.

Active ingredient in this medicine: estradiol

Active ingredient in this medicine: estradiol + dydrogesterone

Information for medicine and pack size:
Femoston 2/10 (14 x 2 mg tablets, 14 x 2 mg/10 mg tablets), 28

Consumer Medicine Information leaflet:

This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.

Read leaflet

What this medicine is for

Hormone Replacement therapy (HRT) in oestrogen deficiency associated with natural or artificial menopause in women with an intact uterus. Prevention of postmenopausal bone mineral density loss in women. For initiation and continuation of treatment of postmenopausal symptoms, the lowest effective dose for the shortest duration should be used with the goal being short term use (See DOSAGE AND ADMINISTRATION and CLINICAL TRIALS). When prescribed solely for the prevention of postmenopausal bone mineral density loss in women, therapy should only be prescribed for women who are at high risk of future fracture and who are intolerant of, or contraindicated for non-oestrogen products approved for prevention of osteoporosis. Life style modifications and the risk benefit profile of FEMOSTON should be taken into careful consideration and discussed with the patient, to allow the patient to make an informed decision prior to prescribing( See PRECAUTIONS and DOSAGE AND ADMINISTRATION).

Table of characteristics
Table of characteristics
Active ingredient
Medicine schedule
28 tablets (14 of each tablet): Prescription Only Medicine, or Prescription Animal Remedy
84 tablets (42 of each tablet): Prescription Only Medicine, or Prescription Animal Remedy
Part 1
Part 1
Visual appearance Round, biconvex, brick-red film-coated tablet, bearing the inscription "379" on one side.
Dosage Form Tablet, film coated
Route of administration Oral
Part 2
Part 2
Visual appearance Round, biconvex, yellow, film-coated tablet, bearing the inscription "379" on one side.
Dosage Form Tablet, film coated
Route of administration Oral

There is one type of pack available.

Pack type 1
Pack type 1
Type Blister Pack
Storage temperature Store below 30 degrees Celsius
Storage conditions No information available
Life time 3 Years
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on 1 February 2018

The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.

Go to PBS site

Is this medication banned in sport?

Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.

Go to ASADA site

The information displayed on this page is authored by Healthdirect Australia, or obtained from trusted sources.

Need more information?

These trusted information partners have more on this topic.

Healthdirect 24hr 7 days a week hotline

24 hour health advice and information you can count on

1800 022 222

Government Accredited with over 140 information partners

We are a government-funded service, providing quality, approved health information

Australian Government, health department logo ACT Government logo New South Wales government, health department logo Northen Territory Government logo Government of South Australia, health department logo Tasmanian government logo Government of Western Australia, health department logo